NeoVax Plus Ipilimumab in Renal Cell Carcinoma

NCT02950766 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Kidney Cancer

Interventions

DRUG: NeoVax
DRUG: Ipilimumab

Sponsor

Patrick Ott, MD, PhD

Collaborators

[object Object]
[object Object]